Search
Benitec Biopharma Inc
BNTCAdd to Watchlist
10.890USD
-0.600-5.22%
Close 05/18, 16:00（ET）Quotes delayed by 15 min
373.04MMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-5.22%
5 Days
-9.85%
1 Month
-22.66%
6 Months
-19.51%
Year to Date
-19.15%
1 Year
-19.93%
TradingKey Stock Score of Benitec Biopharma Inc
Currency: USD Updated: 2026-05-15Key Insights
Benitec Biopharma Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 52 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 26.00.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Benitec Biopharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Benitec Biopharma Inc Highlights
StrengthsRisks
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -12.45, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 33.05M shares, increasing 13.43% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 1.36K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.09.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
25.800
Target Price
+124.54%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Benitec Biopharma Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Benitec Biopharma Inc Info
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
Ticker SymbolBNTC
CompanyBenitec Biopharma Inc
CEOBanks (Jerel A)
Websitehttps://benitec.com/
Related Instruments
-1.67%
+1.29%
+0.97%
-0.47%
+0.72%
+1.06%
-0.59%
+0.07%
-1.03%
0.00%
+0.54%
-0.08%
+1.99%
+1.19%
+2.02%
0.00%
-9.82%
-0.24%
-2.88%
+2.34%Popular Instruments
102.173
-0.283 (-0.28%)
297.840
-2.390 (-0.80%)
222.320
-3.000 (-1.33%)
4568.490
+2.370 (+0.05%)
458.680
-23.340 (-4.84%)
1333.010
-74.600 (-5.30%)
681.540
-43.120 (-5.95%)
396.940
+0.160 (+0.04%)
76799.980
-79.940 (-0.10%)
409.990
-12.250 (-2.90%)
